MonumenTAL-8

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

• Ciltacabtagene Autoleucel (cilta-cel) is a BCMA-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient’s own T-cells with a transgene encoding a chimeric antigen receptor (CAR) that identifies and eliminates cells that express the B-cell maturation antigen (BCMA).
• Daratumumab is a type of cancer drug called a monoclonal antibody. Daratumumab attaches to a protein called CD38, which is present in high numbers on the surface of multiple myeloma cells, as well as on certain other types of cells, such as red blood cells.
• Dexamethasone is a corticosteroid that prevents the release of substances in the body that cause inflammation, and is given in conjunction with some cancer treatments.
• Lenalidomide is an oral immunomodulatory drug that may help the immune system kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow.
• Talquetamab is a bispecific antibody that binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells. 

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.